BioPharma Reporter, July 25, 2007 The $597,000 grant will go towards a Dengue fever vaccine which makes use of VaxInnate's innovative TLR technology, potentially creating the first and only vaccine for this type of infection.  The company's development program hopes to be able to produce a vaccine capable of protecting against all four different serotypes of the Dengue virus. "The greatest difficulty in developing a tetravalent vaccine has been in formulation," Jeff Powell, vice president of research, and William McDonald, group leader of biochemistry at the company explained to US-PharmaTechnologist.com. VaxInnate, in collaboration with the University of Texas Medical Branch (UTMB), hopes to be able to achieve this tetravalent protection by using the company's TLR technology to develop a vaccine where other production methods have failed. The NIH grant to support the development of a Dengue fever vaccine comes on the back of positive proof of principle studies in West Nile virus, which showed that the TLR technology could have applications in a number of Flavivirus diseases, including Dengue fever.